688013.SH
Touchstone International Medical Science Co., Ltd.
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 25.22
−0.32%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 316.6M | 326.7M | 272.4M | 253.6M | 232.0M |
| Cost of Revenue | 110.5M | 117.9M | 113.1M | 111.4M | 99.1M |
| Gross Profit | 206.1M | 208.9M | 159.3M | 142.3M | 132.9M |
| Operating Expenses | |||||
| R&D Expense | 55.4M | 51.3M | 36.0M | 35.3M | 34.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 33.0M | 34.1M | 35.2M | 30.5M | 29.0M |
| Selling & Marketing Expense | 46.7M | 47.7M | 39.7M | 41.6M | 32.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 132.8M | 126.0M | 111.4M | 105.9M | 95.1M |
| Cost and Expenses | 243.3M | 243.9M | 224.5M | 217.3M | 194.2M |
| Operating Income (EBIT) | 90.7M | 95.6M | 55.0M | 46.4M | 44.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 90.2M | 95.2M | 54.8M | 47.9M | 46.1M |
| Income Tax Expense | 8.5M | 10.0M | 2.9M | 636.1K | 2.9M |
| Bottom Line | |||||
| Net Income | 81.7M | 85.2M | 51.9M | 47.3M | 43.2M |
| Earnings from Cont. Ops | 81.7M | 85.2M | 51.9M | 47.3M | 43.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 81.7M | 85.2M | 51.9M | 47.3M | 43.2M |
| Per Share | |||||
| Basic EPS | CN¥1.02 | CN¥1.06 | CN¥0.65 | CN¥0.60 | CN¥0.54 |
| Diluted EPS | CN¥1.02 | CN¥1.05 | CN¥0.64 | CN¥0.58 | CN¥0.53 |
| Revenue Per Share | CN¥3.92 | CN¥4.07 | CN¥3.41 | CN¥3.22 | CN¥2.90 |
| Shares | |||||
| Basic Shares Outstanding | 80.8M | 80.4M | 79.8M | 78.9M | 80.0M |
| Diluted Shares Outstanding | 80.8M | 80.4M | 79.8M | 78.9M | 80.0M |
| Profitability Metrics | |||||
| EBITDA | — | 107.6M | 64.8M | 55.6M | 52.3M |
| D&A | — | 12.0M | 9.8M | 9.2M | 8.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026